EHS
EHS

Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique

Oyster Point Pharma logoLarge pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops.

Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach.

“What we’ve come up with is a very innovative nasal spray, which when sprayed into the nose penetrates the naval cavity quite rapidly, binds to the [nicotinic acetylcholine] receptors, and can actually stimulate the patient’s natural tear production,” CEO Jeffrey Nau told Drug Delivery Business News. “It’s really the first of its kind in the pharmaceutical field to use this class of drugs to stimulate those receptors on the trigeminal nerve.”

Get the full story at our sister site, Drug Delivery Business News.

The post Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique appeared first on MassDevice.

EHS
Back to top button